Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Kerwin (Medford, OR, United States of America), C. Vogelmeier (Marburg, Germany), F. Maltais (Quebec, Canada), I. Boucot (Brentford, Middlesex, United Kingdom), L. Tombs (Uxbridge, Middlesex, United Kingdom), I. Naya (Brentford, Middlesex, United Kingdom), P. Jones (Brentford, Middlesex, United Kingdom), T. Keeley (Uxbridge, Middlesex, United Kingdom), D. Lipson (Collegeville and Philadelphia, PA, United States of America), C. Compton (Brentford, Middlesex, United Kingdom), L. Bjermer (Lund, Sweden). Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial. 2477

Member's Comments

No comment yet.

Related content which might interest you: Improvements in lung function with umeclidinium/vilanterol analysed by reversibility at screening: a post hoc analysis of the EMAX trial Source: Virtual Congress 2021 – Inhaled treatments for COPD: clinical trials and real-world studies Year: 2021 Characterising patients with COPD by baseline short-acting ß2-agonist (SABA) use: a post hoc analysis of the EMAX trial Source: Virtual Congress 2020 – Clinical studies of COPD: combination inhalers and much more Year: 2020 Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Predictors of loss of asthma control in the Phase 2a INCONTRO trial: A post-hoc analysis Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 FF/UMEC/VI versus FF/VI and UMEC/VI in the ELLIPTA device in patients with COPD: Subgroup analyses from the IMPACT trial Source: International Congress 2018 – COPD management Year: 2018 Circulating desmosine as a biomarker of azithromycin treatment response: a post hoc analysis of the COLUMBUS randomised controlled trial Source: ERJ Open Res, 4 (4) 00136-2018; 10.1183/23120541.00136-2018 Year: 2018 Once-daily QVA149 improves dyspnoea and health status compared with tiotropium plus formoterol in patients without ICS use: A post-hoc analysis of the QUANTIFY study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Efficacy of aclidinium/formoterol: pooled post hoc analysis of patients naïve to COPD maintenance therapy Source: International Congress 2017 – COPD management Year: 2017 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Benefits of tiotropium/olodaterol compared with tiotropium in patients with COPD receiving only LAMA at baseline: pooled analysis of 4 clinical trials Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Cost-effectiveness of tiotropium versus salmeterol: A trial-based analysis followed by a model-based extrapolation Source: Annual Congress 2011 - Understanding the burden of chronic respiratory diseases: what decision makers need to know Year: 2011 Efficacy of weight-based reslizumab dosing is consistent across body weights in post-hoc analysis Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018 Treatment response in COPD: does FEV1 say it all? A post hoc analysis of the CRYSTAL study Source: ERJ Open Res, 5 (1) 00243-2018; 10.1183/23120541.00243-2018 Year: 2019 Impact of turnaround time on outcome with point-of-care testing for respiratory viruses: a post hoc analysis from a randomised controlled trial Source: Eur Respir J, 52 (2) 1800555; 10.1183/13993003.00555-2018 Year: 2018 Indacaterol once-daily improves symptom control in COPD patients: a 52-week evaluation vs placebo (pbo) and formoterol (for) Source: Annual Congress 2009 - New bronchodilators Year: 2009 Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials Source: ERJ Open Res, 7 (1) 00816-2020; 10.1183/23120541.00816-2020 Year: 2021 Efficacy of indacaterol/glycopyrronium versus salmeterol/fluticasone in current and ex-smokers: a pooled analysis of IGNITE trials Source: International Congress 2018 – COPD management Year: 2018 A multicenter, randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the fluticasone/salmeterol (500/50 μg) combination administered with the new Elpenhaler inhalation device versus the innovative one in patients with asthma Source: Annual Congress 2009 - Quality of treatment in primary respiratory care Year: 2009 Mometasone/ indacaterol/ glycopyrronium demonstrates similar efficacy in men and women: post hoc analysis of IRIDIUM study Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence Year: 2021 Cost-effectiveness of the fixed-dose combination tiotropium + olodaterol based on the DYNAGITO trial results Source: International Congress 2018 – COPD, asthma and tuberculosis: benefits related to therapy costs Year: 2018